Immunic announces offering of warrants to purchase common stock

Immunic (IMUX) announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on December 31, 2025, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. All of the securities to be sold in the proposed offering will be offered by Immunic. The company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes. Leerink Partners is acting as the sole bookrunner for the offering.